Literature DB >> 21030999

Cancer: Targeting mutant BRAF in metastatic melanoma.

Alexandra Flemming.   

Abstract

Entities:  

Year:  2010        PMID： 21030999     DOI： 10.1038/nrd3304

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  3 in total

1.  Inhibition of mutated, activated BRAF in metastatic melanoma.

Authors:  Keith T Flaherty; Igor Puzanov; Kevin B Kim; Antoni Ribas; Grant A McArthur; Jeffrey A Sosman; Peter J O'Dwyer; Richard J Lee; Joseph F Grippo; Keith Nolop; Paul B Chapman
Journal:  N Engl J Med       Date:  2010-08-26       Impact factor: 91.245

2.  RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models.

Authors:  Hong Yang; Brian Higgins; Kenneth Kolinsky; Kathryn Packman; Zenaida Go; Raman Iyer; Stanley Kolis; Sylvia Zhao; Richard Lee; Joseph F Grippo; Kathleen Schostack; Mary Ellen Simcox; David Heimbrook; Gideon Bollag; Fei Su
Journal:  Cancer Res       Date:  2010-06-15       Impact factor: 12.701

3.  Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma.

Authors:  Gideon Bollag; Peter Hirth; James Tsai; Jiazhong Zhang; Prabha N Ibrahim; Hanna Cho; Wayne Spevak; Chao Zhang; Ying Zhang; Gaston Habets; Elizabeth A Burton; Bernice Wong; Garson Tsang; Brian L West; Ben Powell; Rafe Shellooe; Adhirai Marimuthu; Hoa Nguyen; Kam Y J Zhang; Dean R Artis; Joseph Schlessinger; Fei Su; Brian Higgins; Raman Iyer; Kurt D'Andrea; Astrid Koehler; Michael Stumm; Paul S Lin; Richard J Lee; Joseph Grippo; Igor Puzanov; Kevin B Kim; Antoni Ribas; Grant A McArthur; Jeffrey A Sosman; Paul B Chapman; Keith T Flaherty; Xiaowei Xu; Katherine L Nathanson; Keith Nolop
Journal:  Nature       Date:  2010-09-30       Impact factor: 49.962
  3 in total
  4 in total

Review 1.  Adolescent and young adult patients with cancer: a milieu of unique features.

Authors:  Leonard Sender; Keri B Zabokrtsky
Journal:  Nat Rev Clin Oncol       Date:  2015-05-26       Impact factor: 66.675

2.  Mutant-selective degradation by BRAF-targeting PROTACs.

Authors:  Shanique Alabi; Saul Jaime-Figueroa; Zhan Yao; Yijun Gao; John Hines; Kusal T G Samarasinghe; Lea Vogt; Neal Rosen; Craig M Crews
Journal:  Nat Commun       Date:  2021-02-10       Impact factor: 14.919

3.  Development of a potent small-molecule degrader against oncogenic BRAFV600E protein that evades paradoxical MAPK activation.

Authors:  Nobumichi Ohoka; Masanori Suzuki; Takuya Uchida; Yoshinori Tsukumo; Masayuki Yoshida; Takao Inoue; Hitoshi Ohki; Mikihiko Naito
Journal:  Cancer Sci       Date:  2022-06-05       Impact factor: 6.518

Review 4.  Parkinson's Disease and Melanoma: Co-Occurrence and Mechanisms.

Authors:  Anindita Bose; Gregory A Petsko; David Eliezer
Journal:  J Parkinsons Dis       Date:  2018       Impact factor: 5.568
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.